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1. Introduction 
Melanoma is the malignant tumor of melanocytes, skin cells which produce the pigment 
melanin. According to the 2010 statistics from American Cancer Society, around 68,130 new 
cases will be diagnosed with melanoma, of which 8,700 individuals will die 
(http://www.cancer.gov/cancertopics/types/melanoma). Melanoma is one of the most 
fatal forms of skin cancer, accounting for almost 65% of all the skin cancer related deaths. 
Despite a decrease in the mortality rate in the population under the age of 65 years, the 
incidence of melanoma has increased annually in both Caucasian men and women. It is 
ranked as the 5th most common cancer in men and the 6th most common cancer in women 
(Sober et al., 2008). Additionally, the 5-year survival for the metastatic melanoma is still 
significantly high, when compared to the non-metastatic type (O’Day et al., 2002). This is 
due, in part, to the relative resistance of metastatic melanoma to chemotherapeutic agents 
(O’Day et al., 2002). Thus, it is essential to develop new therapeutic agents targeting unique 
molecular signaling pathways important for the development of the malignant and invasive 
neoplasm. 
Factors which predispose individual to developing melanomas include, among others, 
exposure to sunlight (UVB irradiation) (Lee, 1982). UVB radiation is linked to DNA damage 
and depressed immune function. This is supported by demographic data which show high 
prevalence of melanomas in white skin individuals living in the equatorial zone (compared 
to those living in northern latitudes) (Lee and Scotto, 1993), the prevalence of melanomas to 
sun exposed areas of the body, early exposures and sunburns, and increased outdoor 
recreational sports (Balch et al., 1997). However, sunlight may not be the only cause, but one 
of several causes. For example, the incidence of melanomas is higher in white collar workers 
(mostly likely to work inside) than in blue collar workers (more likely to work outside). 
Susceptibility to sunburns, light skin color and freckling are associated with increased 
incidence of melanomas (Balch et al., 1997). Measures which could be taken to decrease the 
incidence of melanomas include the use of UV-A/UV-B sunblock with sun protection factor 
≥15, avoiding mid-day sunlight, restriction of activity in a shaded area, and the use of 
umbrellas and protective clothing. In addition, it is also recommended that individuals 
avoid tanning in a UV tanning salon (Balch et al., 1997). 
Several genes have been identified which increases susceptibility to melanomas. These 
include p16, the product of which regulates the cell cycle by inhibiting cyclin-dependent 
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kinase 4 (cdk4) (Serrano et al., 1993). Mutation of this gene would allow for uncontrolled cell 
proliferation. Screening could identify patients who are likely to develop melanoma and 
help them to institute life-style changes to limit UV exposure.  
Melanoma progresses from a common acquired nevus to a primary dysplastic nevus. This 
can then develop into a primary melanoma and subsequently to metastatic melanoma. Early 
detection of melanoma is essential for initiation of its management. This is aided by 
evaluation of antigenic markers linked to differentiation and pathogenesis. One such 
protein, S-100 protein, is expressed in all melanomas and could serve as a marker for 
melanoma (Harpio and Einarsson, 2004). However, it is also expressed in sarcomas and 
other cancers. Another protein, HMB-45, is more specific for melanoma but is not always 
accurate for metastatic melanoma (Wick et al., 1988). Various other markers include 
cytokeratins and leukocyte common antigen.  
Management of melanoma includes surgical excision of the superficial skin lesions and local 
metastases which are accessible. In addition, radiation of cutaneous and lymph node 
metastases could be performed. Chemotherapy is also useful for the management of 
melanoma. The infusion of the alkylating agent, decarbazine, is a standard treatment. Other 
agents include melphalan, nitrosureas, platinum compounds, vincristine and others. 
However, the response rates of chemotherapy are low, ranging from 10-23%. In some cases, 
limb perfusion with melphalan alone or in combination with immune modulators, such as 
tumor necrosis factor-α (TNF-α) and interferons (IFNs) have been shown to be effective. 
However, the prolonged use of IFNs is limited by the development of flu-like symptoms 
and hepatotoxicity (Atallah and Flaherty, 2005). Other forms of immunotherapy, such as the 
use of tumor vaccines and monoclonal antibodies, are under investigation (Weber, 2011). 
Melanomas are associated with specific antigens on their cell surfaces, which serve as 
homing targets of cytotoxic T cells (CTLs). These include MAGE-1 (Van der Bruggen et al., 
1991; De Plaen et al., 1994), which could be a suitable target for immune-based therapies 
(Marchand et al., 1993). Other targets include tyrosinase and MART-1 melanoma antigens 
(Kawakami and Rosenberg, 1996). CTLs generated against these proteins could serve as 
novel targets for immunotherapy. 
This chapter provides a review of studies on the types of adenosine receptors present on 
melanoma cells and discusses how these receptors mediate the progression or inhibit the 
growth and metastasis of melanoma. These receptors present on melanoma cells or immune 
cells mediate a direct or indirect effect on the growth and metastasis of melanoma. Selective 
agonists or antagonists of these receptor types could serve as novel treatments for 
melanoma.  
2. Adenosine and its receptors 
Adenosine is a purine nucleoside composed of adenine attached to a ribose molecule via 
glycosidic linkage. It is a ubiquitously produced by stepwise dephosphorylation of ATP. 
Extracellular adenosine acts as a signaling molecule which mediates a number of 
physiological and metabolic effects (Gorlach, 2005). Adenosine accumulation during 
ischemia and inflammation protects tissue from injury (Linden, 2001). Some effects of 
adenosine which are considered tissue or cytoprotective are mediated by a variety of 
cellular mechanisms. These include stimulation of glycogen breakdown to provide glucose 
for ATP production via anaerobic glycolysis, reduction in neuronal excitability as well as 
neurotransmitter release to reduce neuronal energy demands (Gorlach, 2005), increasing the 
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ratio of oxygen supply to demand by causing vasodilation, reducing inflammation and 
promoting angiogenesis (Adair, 2005; Jacobson and Gao, 2006).  
The idea that adenosine has an important role in cardiovascular function was first 
introduced more than 80 years ago when Drury and Szent-Gyorgyi (1929) found that extracts 
from heart and other tissues produced vasodilation, hypotension, bradycardia, and a decrease 
in atrioventricular conduction velocity. It was later shown by Berne et al (1983) that 
adenosine acts as a retaliatory metabolite which tend to counter the processes which led to 
increased oxygen demand. This action helps to maintain tissue oxygenation within a normal 
range in hypoxia. Such a retaliatory action could be demonstrated in the heart, brain, and 
skeletal muscle, where adenosine increases oxygen supply by promoting vasodilation and 
increased blood flow to these tissues (Berne et al., 1983). Adenosine also mediates an anti-
adrenergic effect which decreases oxygen demand in the heart (Adair, 2005). While these 
actions of adenosine are relatively short-term, the nucleoside can also promote long-term 
changes to enhance survival. For example, adenosine promotes angiogenesis, a process of 
new blood vessel growth (Adair, 2005). Angiogenesis may be important in coronary artery 
disease, ischemia, stroke and in delayed wound healing for the repair and regeneration of 
tissue (Gupta and Zhang, 2005). Such an action may also provide oxygen and nutrient to 
tumors as they grow away from their primary blood vessel supplies. 
2.1 Adenosine: Formation and metabolism  
Adenosine accumulates in tissues when oxygen demand exceeds oxygen supply, as would 
be encountered during vigorous exercise or during an ischemic attack (Adair, 2005) or in the 
microenvironment of tumors. It is generated and metabolized through stepwise 
dephosphorylation of ATP (Figure 1). ATP and ADP are converted by CD39 (ecto-ATP 
apyrase) to AMP through a process activated by hypoxia (Gorlach, 2005). 
Dephosphorylation of AMP is mediated intracellularly by cytosolic-5′-nucleotidase and 
extracellularly by membrane-bound ecto-5′-nucleotidase (CD73), respectively. Intracellularly, 
adenosine is also produced from the hydrolysis of S-adenosylhomocysteine (SAH). 
However, hydrolysis of SAH to adenosine contributes marginally to its production (Adair, 
2005). Adenosine deaminase is widely distributed in many cells and tissues where it 
metabolizes adenosine to form inosine and hypoxanthine. Adenosine kinase catalyses the 
formation of AMP from adenosine in order to replenish the stores of cellular ATP (Adair, 
2005; Gorlach, 2005). 
The cellular uptake and release of adenosine is accomplished by two main groups of 
membrane nucleoside transporters. Concentrative nucleoside transporter family (SLC28) is 
found in specialized epithelial tissue and it mediates active Na+-dependent nucleoside 
transport. Passive nucleoside transport processes are ubiquitous and are mediated by 
members of the equilibrative nucleoside transporter (ENT) family (SLC29) (Baldwin et al., 
2004). ENTs are bidirectional and four ENT isoforms are identified in human and rodent 
genome. Inhibition of ENTs by dipyridamole, a coronary vasodilatory and cardio-protective 
agent, prevents the reuptake of adenosine into the endothelial cells, increases its 
extracellular concentration and thus enhances AR activation (Adair, 2005; Gorlach, 2005). 
Thus, extracellular adenosine concentrations can increase by increasing the activities of 
nucleotidases (major pathway) and adenosine kinases (minor pathway) along with their 
substrates (such as AMP). In addition, inhibition of ENTs would also lead to increased 
extracellular adenosine (Adair, 2005). Exposing cells to a hypoxic environment can increase 
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the activities of nucleotidases and decrease the activities of adenosine kinases, leading to a 
net increase in the production of adenosine (Linden, 2001). The induction of ecto-5’-
nucleotidase (CD73) activity in hypoxic condition has been shown in the ischemic heart 
(Minamino et al., 1996) and brain (Braun et al., 1997) of intact animal, possibly by hypoxia 
inducible factor (HIF-1- dependent pathway (Synnestvedt et al., 2002). Hypoxia also down-
regulates ENT1 expression in different mouse tissues (Chaudry et al., 2004; Eltzschig et al., 
2005), thereby increasing extracellular concentrations of adenosine. 
Higher adenosine concentrations in the extracellular fluids are important to activate the ARs 
present on a variety of cells. Studies have estimated the physiological extracellular 
adenosine concentrations in normal brain to be approximately 30-300 nM (Fredholm et al., 
2001). In vivo studies by Blay et al. (1997) revealed that the adenosine concentrations in the 
extracellular fluids of solid tumor in mice range from 0.2-2.4 µM, which is 10- to 20-fold 
higher compared to concentrations in adjacent subcutaneous tissue. Furthermore, treatment 
with inhibitors of adenosine deaminase and adenosine kinase can increase adenosine levels 
in tumors to as high as 13 µM (Blay et al., 1997). 
 
 
Fig. 1. Metabolic pathways for adenosine production and consumption. Adenosine is 
produced by the dephosphorylation of ATP and ADP by ATPases and the action of  
5’-nucleotidase. Additionally, the nucleoside is produced from SAH by SAH hydrolase. 
Once produced, adenosine could be transported in or out of the cell by bidirectional 
transporters , ENT1 and 2. Adenosine is rapidly degraded by adenosine deaminase. 
Abbreviations: ATPase, ATP hydrolyzing enzymes; AdK, adenylate kinase; SAH,  
S-adenosylhomocysteine; ENT: Equilibrative nucleoside transporter. The arrow heads  
and  indicate up-regulation or down-regulation of enzymes and the transporter during 
hypoxia. [Modified from (Adair, 2005; Gorlach, 2005)] 
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2.2 Adenosine receptors  
Studies have shown that adenosine levels are highest in the tumor microenvironment which 
is severely hypoxic. The physiological concentrations of adenosine produced under such 
conditions are sufficient enough to activate ARs present on the tumor cells (Ohta et al., 
2006). The effects of extracellular adenosine are mediated by four known ARs subtypes, 
namely the A1, A2A, A2B and A3AR. All of these ARs are cell surface G protein-coupled 
receptor which have distinct tissue-specific distributions (Fredholm et al., 2001). These ARs 
were classified on the basis of their inhibiting (A1 and A3AR) or stimulating (A2A and A2BAR) 
adenylyl cyclase by coupling to either Gi or Gs types of guanine nucleotide regulatory (G) 
proteins, respectively (Fredholm et al., 2006). Inhibition or activation of adenylyl cyclase 
reduces or increases intracellular cyclic AMP, respectively. This second messenger mediates 
a number of cellular functions, which could be altered depending on the presence of 
extracellular adenosine and the AR profile expressed on the cell surface. In addition, there is 
some evidence that the ARs may signal via other G-proteins (Fredholm et al., 2001), which 
activate other pathways such as phospholipase C (PLC), Ca2+ and mitogen-activated protein 
kinases (MAPKs) (Jacobson and Gao, 2006). Activation of A1AR inhibits adenylyl cyclase by 
stimulating pertussis toxin-sensitive Gi proteins, leading to increased activity of PLC. The 
A1AR is also coupled to the activation of K+ channels and inhibition of N-, P- and Q-type 
Ca2+ channels (Fredholm et al., 2001; Jacobson and Gao, 2006). The same appears to be true 
for A3AR, which also binds to Gq G-proteins and activates PLC (Fredholm et al., 2001). In 
contrast, the A2AAR interacts with the stimulatory Gs and Golf G-proteins to activate adenylyl 
cyclase and increase cyclic AMP concentrations (Fredholm et al., 2001). Activation of A2AAR 
also induces the formation of inositol 1,4,5-trisphosphate (IP3) to raise intracellular Ca2+ and 
activate PKC in COS-7 cells via pertussis toxin-insensitive Gα15 and Gα16 proteins (Fredholm 
et al., 2001). Like the A2AAR, the A2BAR is positively coupled to both Gs and Gq proteins and 
therefore can modulate both intracellular cyclic AMP and IP3 concentrations (Fredholm et 
al., 2001). A2BAR has lower affinity for adenosine as compared to A2AAR (Feoktistov and 
Biaggioni, 1997). A2AAR expression could be induced by inflammatory cytokines, such as 
interleukin (IL)-1 and tumor necrosis factor (TNF)-ǂ (Khoa et al., 2001). A2BAR expression is 
induced by hypoxia inducible factor (HIF)-1ǂ in hypoxia (Kong et al., 2006), TNF-α and 
interferon (IFN)-Ǆ (St Hilaire et al., 2008; Xaus et al., 1999). Such regulations could be 
important in a tumor microenvironment associated with significant hypoxia and/or 
inflammation. 
Several studies have shown that the adenosine-induced activation of MAPK is essential for 
mediating cell differentiation, survival, proliferation, and death (Fredholm et al., 2001). 
Extracellular regulated kinases (ERK1/2) are members of the MAPK family linked to 
cellular proliferation. A1AR transiently expressed in COS-7 cells activated ERK1/2 via ǃ,Ǆ-
subunits released from Gi/o G-proteins (Faure et al., 1994). Studies on stably expressed A1AR 
in CHO cells demonstrated that the A1AR can also induce ERK1/2 activation (Dickenson et 
al., 1998; Schulte and Fredholm, 2000). A2AAR activation stimulates ERK1/2 via a cyclic 
AMP/Ras/MAPK kinase pathway in endothelial cells (Sexl et al., 1997). A2BAR-mediated 
activation of MAPK is important for interleukin (IL)-8 secretion, a pro-angiogenic growth 
factor, and consequently for mast cell activation (Fredholm et al., 2001). Another pathway 
has been demonstrated in human umbilical vascular endothelial cell (HUVEC) which 
involves cyclic AMP-dependent but protein kinase A (PKA)-independent activation of 
ERK1/2, associated with cell proliferation (Fang and Olah, 2007). The cyclic AMP activation 
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of exchange protein activated by cyclic AMP-1 (Epac1) stimulates ERK1/2 activity. This 
provides an alternate pathway for ERK1/2 activation by the A2BAR. (Fang and Olah, 2007). 
2.3 Adenosine receptors in cancer 
ARs are differentially expressed on tumor cell lines and tumor samples. High levels of  
A1AR are expressed in breast cancer tissues, compared to normal breast tissues (Mirza et al., 
2005). Activation of the A1AR was shown to reduce the proliferation of these cells by 
inhibiting the G1 checkpoint in the cell cycle (Mirza et al., 2005). Increased A1AR was also 
observed in the peritumoral regions of experimental F98 glioma cells. The sources of the 
increased A1AR expression were activated astrocytes and microglia which suppress 
glioblastoma (Synowitz et al., 2006). In addition, activation of A1AR on colon cancer cells 
increased apoptosis by activating caspases (Saito et al., 2010). Studies have also shown an 
anti-tumor action of A2AAR in A375 melanoma (Merighi et al., 2002) and human colon 
cancer cells (Yasuda et al., 2009), the latter mediated by activation of caspases. In contrast, 
the A2AAR promotes growth of breast cancer MCF-7 breast cancer cells (Etique et al., 2009) 
and increases angiogenesis by inducing VEGF expression (Montesinos et al., 2002). These 
studies suggest that A2AAR antagonists could be useful in cancer by blocking angiogenesis. 
Activation of the A2BAR is also linked to angiogenesis and promotes growth and tumor 
metastasis (Grant et al., 1999). In support of this, A2BAR knockout mice, administered Lewis 
lung carcinoma, demonstrated reduced tumor growth and survival times (Ryzhov et al., 
2008). Studies performed on U87 MG human glioblastoma cells only detected transcripts for 
A1, A2A and A2BARs, but no transcript for A3AR (Zeng et al., 2003). However, Merighi et al. 
(2006) were able to detect A3AR in these cells. A3AR is also highly expressed in tumors like 
colon and breast carcinoma tissues as compared to non-neoplastic or normal tisues (Madi et 
al., 2004). A role of the A3AR in mediating anti-tumor actions in vitro and in vivo has been 
demonstrated. For example, A3AR agonists inhibit the growth of melanoma (Madi et al., 
2003), colon (Ohana et al., 2003) and prostate cancers (Fishman et al., 2004) in animal 
models. Induction of the A3AR occurs in several types of cancers (Madi et al., 2004), when 
compared to normal adjacent tissue, suggesting that these receptors could serve as potential 
molecular markers of these cancers. One study demonstrated inhibition of liver metastasis 
in mice inoculated with human HCT-116 or murine CT-26 colon carcinoma cells by A3AR 
agonists (Ohana et al., 2003). The anti-tumor action of A3AR agonists could be explained by 
an increase in natural killer (NK) cell activity, which promotes killing of tumor cells (Harish 
et al., 2003). 
3. Adenosine receptors in melanoma 
Studies have demonstrated both pro- and anti-tumorigenic effects of AR activation in 
melanoma. Early studies showed that topical application of an A2AAR agonist to the skin 
enhanced wound closure in animals as well as in the animals (Montesinos et al., 1997). 
Adenosine suppressed the proliferation of transformed keratinocytes in both G1 and S 
phases of the cell cycle (Brown et al., 2000). Furthermore, activation of A3AR protected skin 
mast cells from UV light–induced cell death (Gao et al., 2001). This suggests that A3AR 
agonists can also mediate similar protection in different skin cell types. Studies described 
below demonstrate the actions of different AR subtypes on melanoma and support the 
utility of these receptor for treating melanoma. These receptors are described in order of 
their importance in melanoma treatment. 
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3.1 A3 adenosine receptors and melanoma 
The actions of this AR subtype has been best studied in melanoma. This receptor is highly 
expressed in melanoma cell lines and tissues, compared to normal tissues. Measurements of 
the mRNA levels of A3AR in paraffin-embedded melanoma tissue slides showed almost 2-
fold increased expression of A3AR in cancerous tissues, as compared to the normal tissues 
(Madi et al., 2004). Human malignant melanoma A375 cells expressed high levels of A3AR, 
as determined by radioligand binding assays. Activation of these receptors did not decrease 
forskolin-stimulated adenylyl cyclase activity (Merighi et al., 2001), suggesting coupling of 
these receptors to an alternate signaling system. In fact, A3AR activation increased 
intracellular calcium release which was suppressed by an A3AR antagonist. This finding 
suggests that A3AR preferentially couples to a Gq-PLC pathway in A375 melanoma cells. 
Activation of A3ARs in these cells improved survival and reduced A2AAR-induced cell 
death. However, A3AR agonist decreased melanoma cell proliferation in a PKC- and MAPK-
dependent manner. Furthermore, A3AR activation arrested cells in the G1 phase, leading to 
decreased cell number in the G2/M phase (Merighi et al., 2002). The reason for the apparent 
discrepancy between improving survival and decreasing cell proliferation following A3AR 
activation in A375 melanoma cells is unclear. 
In an earlier study, Bar-Yehuda et al. (2001) showed that the A3AR agonist, 1-deoxy- 
1-[6-[((3-iodophenyl)methyl)amino]-9H-purin-9-yl]-N-methyl-ǃ-D-ribofuranuronamide, N6-
(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA), inhibited the growth of 
murine melanoma (B16-F10) cells in culture and suppressed the tumor growth in mice 
injected with these cells. B16-F10 melanoma cells express high levels of A3AR, as detected by 
western blotting, immunocytochemistry and RT-PCR (Madi et al., 2003). The authors 
showed that the A3AR in these cells were negatively coupled to adenylyl cyclase and 
reduced PKA activity. In addition to the primary melanoma growth, the A3AR agonist 
reduced the number of metastatic lung foci, suggesting that A3AR activation also suppresses 
metastasis of these cells. There was also an additive effect of A3AR agonist and 
cyclophosphamide, a chemotherapeutic drug (Fishman et al., 2001). A3AR expression has 
also been studied in another murine melanoma cell line (B16-BL6). Cordycepin, a product of 
the parasitic fungus, Cordyceps sinensis, inhibited the growth of these melanoma cells, both in 
vivo and in vitro by activating the A3AR (Yoshikawa et al., 2008). 
In addition to melanoma cells, A3ARs are also expressed by the anti-tumor T-cells and 
possibly by NK cells (Gessi et al., 2004; Hoskin et al., 2008). A3AR agonist activates NK cells 
in the mouse melanoma model, leading to the suppression of tumor growth and lung 
metastases (Harish et al., 2003). In a recent study, Morello et al. (2011) showed that A3AR 
agonist recruits NK cells to the tumor region to increase the killing of the tumor cells and 
reduce tumor growth.  
The studies described in this section suggest an important anti-tumor action of A3AR 
agonists mediated via inhibition of the cyclic AMP-PKA pathway, which appears important 
for tumor growth. Additionally, due to the additive effects seen with other chemotherapeutic 
drugs, such as cyclophosphamide, the A3AR agonists can also be used as part of a combination 
therapy against melanoma. Importantly, these studies support an indirect role of A3AR in 
mediating its anti-tumor action, primarily via T lymphocytes and NK cells.  
3.2 A2A adenosine receptors and melanoma 
The A2AARs mediate anti-tumor action via a direct and an indirect pathway, the latter 
pathway involving immune cells. Expression of A2AARs in melanoma cell line A375 was  
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first reported by Merighi et al (2001). These cells express A2AAR, as determined by RT-PCR 
and radioligand binding assays. Activation of A2AAR on these melanoma cells increased 
cyclic AMP levels and led to death of melanoma cells (Merighi et al., 2002). 
The A2AAR could mount a significant anti-tumor action against melanoma through an 
indirect mechanism. A2AARs are expressed on CD4+ and CD8+ T-lymphocytes (Koshiba et 
al., 1999), the immune cells that infiltrate the tumor microenvironment as part of the anti-
tumor defense mechanism (Shankaran et al., 2001). The importance of specific anti-
melanoma T-cells lies in the fact that the adoptive transfer of such cells in patients with 
metastatic melanoma resulted in the regression of the tumor at metastatic sites along with 
the mounting of an immune response against the melanoma cells (Dudley et al., 2002). 
Functionally, adenosine and A2AAR specific agonists suppressed the activity of the anti-
tumor T-cells (Butler et al., 2003; Zhang et al., 2004), leading to enhanced tumor growth. In 
fact, mice deficient in A2AAR developed an autoimmune response against the immunogenic 
melanoma cells and complete tumor rejection in ~60% of the mice (Ohta et al., 2006). 
A2AARs have also been studied in lymphokine-activated killer (LAK) cells (Raskovalova et 
al., 2005). LAK cells are the NK cells that become activated by cytokines and demonstrate 
enhanced anti-tumor activity against cancer cells (Zamai et al., 2007). Although expression 
of A2AARs have not been well established in these cells, it has been shown that the LAK cells 
generated from A1AR- and A3AR-deficient mice failed to show any inhibitory effects of 
adenosine. In contrast, LAK cells from A2AAR-deficient mice were resistant to adenosine 
response (Raskovalova et al., 2005). 
The preceding discussion does not provide a clear outcome of the responses of adenosine 
via a direct and indirect pathway in vivo or in the clinical settings. However, the indirect 
pathway of A2AAR action appears to be dominant since inhibition or knockout of these 
receptors enhanced tumor regression in vivo (Ohta et al., 2006, Raskovalova et al., 2007).  
3.3 A2B adenosine receptors and melanoma 
A2BARs are the low affinity adenosine receptors (Fredholm et al., 2001) which are over-
expressed in various tumors (Panjehpour et al., 2005, Li et al., 2005, Phelps et al., 2006). 
These receptors are involved in promotion of the tumor growth (Ryzhov et al., 2008). A2BAR 
has been characterized in A375 human malignant melanoma cells where its activation led to 
increases in cyclic AMP levels (Merighi et al., 2001).  
As with the A2AARs, A2BARs are also expressed by the normal as well as activated T-
lymphocytes (Mirabet et al., 1999). As mentioned above, these activated T-lymphocytes 
provide host defense response against the tumor cells. Similar to the A2AAR, the A2BAR 
inhibits T-lymphocytes function and promotes tumor growth (Ohta et al., 2006). These 
investigators demonstrated that mice in which A2AAR was deleted showed a 60% tumor 
regression, suggesting a tumor enhancing action of the A2BAR (Ohta et al. (2006). 
3.4 A1 adenosine receptors and melanoma 
One of the first studies of ARs in melanoma examined the role of A1AR on the motility of 
A2058 melanoma cells in vitro (Woodhouse et al., 1998). In this study, the authors showed 
that adenosine- and AMP-dependent chemotactic responses of melanoma cells were 
mediated via A1AR stimulation. This response was prevented by A1AR specific antagonist 
and also by pre-treatment with pertussis toxin, to uncouple the A1AR from its G proteins. 
These data implicate the A1AR in chemotaxis of melanoma cells. The normal physiological  
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extracellular concentrations of adenosine are low, ranging between 30-200 nM (Ballarín et 
al., 1991). However, there is a drastic increase in extracellular adenosine levels to 
micromolar levels under conditions of oxidative stress, such as hypoxia and ischemia 
(Rudolphi et al., 1992), as would be expected in the core of the solid tumors. Therefore, is 
highly likely that adenosine produced in the microenvironment of the melanoma could 
facilitate motility and metastasis. One potential target of A1AR-mediated chemotaxis of 
melanoma cells is the central nervous system (Woodhouse et al., 1998). The melanoma cells 
have a high propensity for metastasizing to the brain. Malignant melanoma ranks as the 
fourth most common primary malignancy to metastasize to the brain (Wen et al., 2001), 
with almost 75% prevalence rate determined at autopsies (Patel et al., 1978). One of the 
possible explanations for the increased brain metastases in melanoma could be increased 
adenosine levels in the brain produced by high rates of ATP consumption following 
neuronal activity (Woodhouse et al., 1998). 
A1AR expression along with its biochemical and functional characterization has also been 
described in A375 human malignant melanoma cells (Merighi et al., 2001). It was shown that 
these cells express relatively low levels of A1ARs both at the transcript (as determine by low 
mRNA expression), and at the protein levels (as suggested by the low radioligand binding). 
These investigators observed no significant functional response of A1AR agonist on cyclic 
AMP levels in these cells (Merighi et al., 2001). Furthermore, A1AR antagonist failed to 
suppress the increased levels of IL-8 and VEGF induced by two chemotherapeutic drugs 
(Merighi et al., 2009). These studies suggest that the A1AR are expressed in melanoma cell 
lines used in vitro, which could account for the response to A1AR agonists. Whether the 
A1AR are expressed in melanoma tissues is not yet clear. 
4. Adenosine receptors signaling in melanoma 
The signaling mechanisms involved in the suppression or promotion of melanoma growth 
by adenosine receptors can be further sub-divided into direct (by acting on the melanoma 
cells), or indirect (by regulating the melanoma cell growth via immune cells). 
4.1 Direct signaling mechanisms 
Activation of the A3AR in melanoma has been shown to couple to activation of PLC leading 
(via Gq) to enhanced survival of A375 melanoma cells (Merighi et al., 2001). In contrast, 
activation of the A3AR negatively couples to adenylyl cyclase in melanoma cells which 
suppresses the Wnt signaling pathway. In these cells cyclic AMP, via PKA, increases 
glycogen synthase kinase (GSK)-ǃ and increased phosphorylation of ǃ-catenin. This allow 
for enhanced transcription of genes, such as c-myc and cyclin D, which enhance tumor 
growth. As such, the A3AR suppress tumor growth by inhibiting adenylyl cyclase activity. 
Activation of the A3AR inhibits nuclear factor (NF)-κB, which also negatively regulates 
tumor growth (Fishman et al., 2002; Fishman et al., 2004). 
4.2 Indirect signaling mechanisms 
As discussed above, the A2AAR plays a critical role in tumor progression through their 
inhibitory action on anti-tumor immune cells, such as T-lymphocytes and LAK cells. This 
inhibition is exerted mainly by increasing the levels of cyclic AMP in these cells and 
activating PKA-dependent pathways. In a recently published study, anti-melanoma specific 
CD8+ and CD4+ T-cells activity was suppressed by adenosine and 2-chloroadenosine 
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(Raskovalova et al., 2007). Furthermore, this inhibition was mimicked by A2AAR specific 
agonist 2-p-(2-Carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine hydrochloride 
hydrate (CGS21680), and was blocked by A2AAR specific antagonist, 4-(-2-[7-amino-2-{2-
furyl}{1,2,4}triazolo{2,3-a} {1,3,5}triazin-5-yl-amino]ethyl)phenol (ZM241385). The A2AAR-
dependent effect was mediated by the cyclic AMP/PKA pathway. A2AAR activation 
increased cyclic AMP levels, which activate PKA and regulate different cellular function by 
phosphorylation of cellular targets. PKA consists of two regulatory and two catalytic 
subunits (Francis & Corbin, 1999). Furthermore, two isoforms of PKA are known, PKA-I and 
PKA-II (Chin et al., 2002). In particular, activation of the PKA-I regulatory subunit was 
responsible for the T-cell suppressive effects of adenosine, as blockade of catalytic subunits 
of PKA was not able to reduce the adenosine effects while the PKA-I blocker efficiently 
suppressed the adenosine response (Raskovalova et al., 2007). The inhibitory effects of 
adenosine and its analogues reduced cytotoxicity of anti-melanoma specific T-cells and 
reduced production of cytokines, such as IFN-Ǆ, IL-2 and TNF-α (Raskovalova et al., 2007). 
IFN-Ǆ is one of the critical cytokines involved in the anti-tumor action of the T-cells, as it 
inhibits the process of angiogenesis (Qin and Blankenstein, 2000). Thus, A2AAR inhibition 
could be used in combination with the anti-angiogenic therapy. In this situation, A2AAR 
inhibitors will enhance the immune response against the tumor cells and increase IFN-Ǆ 
secretion, leading to tumor cell killing and decreased angiogenesis. 
Similar to the anti-tumor T-cell inhibition, adenosine and A2AAR-specific agonists also 
reduce the LAK cells-mediated anti-tumor response via cyclic AMP-PKA signaling (Lokshin 
et al., 2006). In addition to the involvement of the regulatory subunit of the PKA, PKA-I, the 
A2AAR-dependent response also exhibits complimentary inhibitory effect on LAK cells 
along with prostaglandin E2 (PGE2) (Lokshin et al., 2006; Su et al., 2008). The co-operative 
response of adenosine and PGE2 involves amplification of the cyclic AMP-PKA signaling, in 
addition to the increased CREB phosphorylation and inhibition of Akt (Su et al., 2008). This 
co-operative response of adenosine and PGE2 also leads to the activation of Csk, an inhibitor 
of the T-cell receptor (TCR) signaling (Su et al., 2011). Activated Csk in turn inhibits Lck, 
ZAP-70 and phosphorylated Akt. The interesting aspect of this co-operative action of 
adenosine and PGE2 is that pre-treatment with sub-suppressive doses of adenosine or PGE2 
results in lack of inhibition of the tumor infiltrating lymphocytes (TILs). This effect is 
explained due to cross desensitization of the PGE2 and ARs. This process gives a new 
direction for the use of adoptive immunotherapy against the tumor cells. It is possible to 
improve the effectiveness of the anti-tumor immune cells by pre-treating them with low 
doses of PGE2 or A2AAR agonist before their adoptive transfer (Su et al., 2011). 
In contrast to the above mentioned mechanisms of A2AAR in regulating the immune cells in 
the tumor microenvironment, an additional concept has been put forward that describes the 
role of A2AARs in suppressing the activation-induced cell death (AICD) of the CD4+ T cells 
(Himer et al., 2010). AICD is a phenomenon that results from TCR-mediated stimulation of 
the already activated T-cells, resulting in apoptosis. This action involves the interaction of 
Fas and Fas ligand (Green et al., 2003). Activation of A2AAR by specific agonist reduced the 
expression of Fas and Fas ligand and prevented the killing of CD4+ cells by AICD. This 
process was PKA-dependent and it also involved the suppression of various transcription 
factors, such as NF-κB, nuclear factor of activated T cells (NF-AT) and early growth 
response (Egr)-1 and Egr-3 proteins (Himer et al., 2010). This anti-apoptotic response of 
A2AAR on CD4+ T cells could promote a prolonged immune response by these cells. This 
action contrasts the inhibitory actions of A2AAR on T-lymphocytes and LAK cells, which 
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reduces their anti-tumor immune response. Although, this anti-AICD process has not been 
described in connection to the tumor cells, it will be interesting to determine if this is also 
true in the anti-tumor immune cells. 
Although, A2A and A2B ARs have been primarily studied in context to anti-tumor immune 
cells functions, immune cells also express A3ARs (Hoskin et al., 2008). However, in contrast 
to the A2A and A2BAR, activation of A3AR boost the anti-tumor immune response (Harish et 
al., 2003; Morello et al., 2011). Treatment with A3AR agonist in the murine B16-F10 
melanoma model resulted in an increased infiltration and activation of the NK and CD8+ T 
cells in the melanoma tissues which was associated with increased levels of IL-12. 
Furthermore, transfer of splenocytes from the A3AR agonist-treated mice suppressed 
metastasis to the lungs of recipient mice (Harish et al., 2003). In contrast, treatment of nude 
mice with A3AR agonist failed to have any effect on the melanoma growth (Morello et al., 
2011). This effect of A3AR agonist on NK and T-cells was associated with increased TNF-ǂ 
and IFN-Ǆ levels in the melanoma tissues, suggestive of heightened immune response 
against the tumor cells (Morello et al., 2011). Thus, the use of A3AR agonists can provide 
strong anti-tumor actions on melanoma cells by a direct inhibitory effects on the tumor cells 
and indirectly via activation of the immune system.  
5. Reactive oxygen species and melanoma 
A number of studies support a role of reactive oxygen species (ROS) in the proliferation and 
metastasis of melanoma cells. For example, ROS can select for chemoresistance by increasing 
the expression of glutathione, an antioxidant. ROS can promote cell survival through 
activation of NF-κB and MAPK pathways and inhibition of p53. ROS can also promote 
melanoma metastasis. High ROS levels in the tumor microenvironment is important for 
killing melanoma cells that are susceptible to ROS and for “selecting” those cells which are 
resistant. These resistant cells are endowed with higher levels of glutathione. High ROS 
levels can induce DNA mitochondrial damage in melanoma cells which can facilitate the 
invasive and metastatic process (Poetsch et al., 2004). In addition high levels of ROS can 
induce epigenetic changes through stimulating DNA methylation (Campos et al., 2007), 
which also can promote invasiveness (Seftor et al., 2005). ROS can also contribute to 
increased melanoma cell proliferation by activating redox-sensitive transcription factors, 
such as NF-κB, activator protein-1 (AP-1) and c-myc (Karin et al., 2001). High ROS levels 
could also increase killing of normal cells in the tumor microenvironment (such as vascular 
endothelial cells) and promote extravasation and metastasis (Offner et al., 1992, 1996). ROS 
could also induce expression of cell adhesion molecules on the primary tumor cells and 
endothelial cells which could promote the metastatic process. In support of these findings, a 
number of in vivo studies in experimental animals demonstrated that 
antioxidants/antioxidant enzymes were effective in lowering the metastatic potential of 
melanoma cells (for review, see Joosse et al., 2010). However, all antioxidants/antioxidant 
enzymes were not effective. While catalase and superoxide dismutase clearly demonstrated 
antitumor actions, glutathione appeared to increase metastasis (Joosse et al., 2010).  
However, ROS has also been linked to the antitumor action of drugs against metastatic 
melanoma. The effectiveness of the agent elesclomol against melanoma has been attributed 
to its ability to promote intracellular ROS generation. When used in association with 
paclitaxel in a Phase 2 clinical trial, elesclomol increased the progression-free survival of 
patients to 3.7 months versus 1.8 months for the second group of patients treated with 
paclitaxel alone (Fruehauf and Trapp, 2008). 
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5.1 NADPH oxidase: source of ROS in melanoma 
The nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system is a superoxide 
producing enzyme complex that has historically been studied in the phagocytes as the 
source of respiratory burst against the ingested microbes. However, this enzyme system is 
also found in other tissues including many cancer tissues and cells. NADPH oxidase 
complex consists of different subunits of which gp91phox, p47phox, p67phox and p22phox are 
required for the activity of the enzyme system. The p40phox and small GTP-binding proteins, 
Rac1 and Rap1A, form the holoenzyme component that promote enzyme activity and ROS 
generation (Lassègue & Clempus, 2003). 
Melanoma cell lines express high levels of p22phox, gp91phox, NOX4 (a homolog of gp91phox) 
and p67phox subunits, with relatively lower expression of p47phox subunit (Brar et al., 2002). 
Over expression of these subunits in M1619 melanoma cells is associated with increased 
activity of NADPH oxidase and high ROS generation, which in turn leads to high rates of 
cell proliferation. This process is dependent on the cyclic AMP responsive element (CRE), as 
inhibition of NADPH oxidase suppressed the cell growth as well as CRE-binding activity 
(Brar et al., 2002).  
Both gp91phox and its homolog NOX4 are expressed in melanoma cells and appear to 
mediate differential effects on these cells. NOX4 appears to be critical for the melanoma 
growth. This observation is supported by the following observations. First, increased NOX4 
expression is observed in human melanoma tissues and cell lines. Second, suppression of 
melanoma tumor growth in nude mice could be produced by silencing the NOX4 
expression. Third, inhibition of melanoma cell proliferation and G2-M cell cycle transition in 
cultures is produced by small interfering (si) RNA against NOX4 (Yamaura et al., 2009). 
However, gp91phox subunit might play an important role in the invasiveness and metastasis 
of melanoma cells. The primary melanoma tumors were not different in the gp91 knockout 
mice, compared to wild type, but they showed reduced invasion and lung metastases. 
Additionally, when gp91phox knockout mice were injected with the phagocytes from wild 
type mice, they showed increased in metastatic ability (Okada et al., 2006). 
 In addition to the role of NOX isoforms discussed in the previous paragraph, two other 
subunits of NADPH oxidase, Rac1 and p47phox, also play important roles in ROS generation, 
proliferation and motility of the melanoma cells. Rac1 is a small GTP-binding protein that is 
involved in cell motility and ROS generation as a component of the NADPH oxidase system 
(Hall, 1992; Lassègue & Clempus, 2003 ). In B16F10 melanoma cells, hyaluronidase increased 
ROS generation and cell motility in Rac1-dependent fashion. Furthermore, Rac1 is also 
involved in the membrane translocation and activation of p47phox subunit. Inhibition of Rac1 
activity by a dominant-negative Rac1 (Rac1N17) and by siRNA again p47phox reduced the 
ROS generation by hyaluronidase and the cell migration ability of these cells (Kim et al., 
2008). In addition to stimulating proliferation and motility, both Rac1 and p47phox can also 
regulate differentiation of the melanoma cells. The NADPH oxidase inhibitor, diphenylene 
iodonium, changed the morphology of the melanoma cells, increased the production of 
melanin pigment and also increased the expression of a pro-melanocyte differentiation 
factor microphthalmia–associated transcription factor (MITF). Expression of MITF was also 
increased by suppressing the expression of Rac1 and p47phox by their respective siRNAs 
(Zhao et al., 2008). Hence, targeting the NADPH oxidase system to reduce the high ROS 
levels in melanoma cells could provide an effective therapeutic strategy to suppress the 
growth, migration and metastasis of the melanoma cells. 
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5.2 A3AR inhibits NADPH oxidase 
As discussed above, the A3AR mediates both direct and indirect inhibition of melanoma cell 
growth (see section 4.1 and 4.2). In a recently published study, we showed that one of the 
potential targets for A3AR is the NADPH oxidase ROS generating system (Jajoo et al., 2009). 
In this study A3AR agonist decreased the NADPH oxidase-dependent high ROS generation 
in prostate cancer cells, resulting in inhibition of tumor growth and metastasis (Jajoo et al., 
2009). Although this study was performed in androgen-resistant prostate cancer cells, these 
findings could be applied to the melanoma cells due to inherent similarities with the 
prostate cancer cells at the biochemical and molecular level. First, melanoma cells generate 
high ROS mediated by the NADPH oxidase system. Further, high ROS levels are 
responsible for the tumor cell growth, migration and invasiveness (Brar et al, 2002; Kim et 
al., 2008; Yamaura et al., 2009). Second, A3AR expression is well characterized in melanoma 
cells along with the anti-tumor effects of the A3AR agonists (Merighi et al., 2001; Fishman et 
al., 2002). Third, similar to our findings in prostate cancer cells, melanoma cells also exhibit 
higher levels of cyclic AMP resulting in increased activation of PKA and its downstream 
signaling pathways. Furthermore, A3AR activation in both types of tumor cells exerted its 
effect by regulating the Wnt signaling pathways (Fishman et al., 2002; 2003). Fourth, we 
found increased ERK1/2-MAP kinase activation in the prostate cancer cells, which was 
reduced by A3AR agonist (Jajoo et al., 2009). In melanoma, A3AR activation reduced the p-
ERK1/2 levels and the ERK1/2-MAP kinase pathway (Merighi et al., 2005). As such, we 
propose that inhibition of NADPH oxidase system resulting in reduced levels of ROS 
generation can also account for A3AR mediated anti-melanoma effects. 
 
 
Fig. 2. Proposed mechanism of inhibition of the growth and metastasis of melanoma cells by 
A3AR agonists. Activation of the A3AR is expected to inhibit ERK MAPK activity by 
inhibiting an upstream cyclic AMP-PKA pathway. Inhibition of ERK reduces activation of 
NADPH oxidase, thereby reducing ROS production. ROS contributes significantly to the 
growth and metastasis of melanoma cells 
6. Conclusion 
Adenosine plays an important role in modulating the progression of melanoma. Several AR 
types present on these cells would determine whether endogenously released adenosine 
promote or inhibit tumor growth and metastasis. In general, agonists of the A2A and A2BARs 
are expected to promote the growth and metastasis of melanoma by inhibiting an indirect 
pathway which involves T-lymphocytes and NK cells-promoted killing of melanoma cells. 
As such, antagonists of these receptors should increase activity of these immune cells and 
promote anti-tumor actions. On the other hand, agonists of the A3AR are expected to 
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provide anti-tumor action by activating these receptors directly on melanoma cells to reduce 
proliferation and metastasis. In addition, activation of the A3AR is expected to provide anti-
tumor actions indirectly by activating T-lymphocytes and NK cells to promote tumor cell 
destruction. Therefore, antagonists of the A2A and A2BAR and agonists of the A3AR should 
be considered as potential treatments for melanoma. These drugs could be combined with 
standard treatment regimen to enhance treatment efficacy.  
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